Abstract
Lipo-PGE1 was introduced onto the Japanese market in 1988 and since then it has been widely used in clinical practice. Today, the preparation became applicable clinically also in Korea and China. PGE1 itself is relatively unstable, and amount of PGE1 will be released from LM. Therefore, we recently produced a new lipo-PGE1, in which a chemically stable PGE1 prodrug (AS013) was incorporated into LM. The new lipo-PGE1 showed an enhanced pharmacological activity, and was stable even at room temperature for 3 years. Now in USA its clinical study is ongoing.
